The U.S. District Court for the Western District of New York recently allowed the majority of two health centers’ state antitrust claims to proceed against four diabetes drug manufacturers.
340B Health and two health systems have asked a federal judge for permission to join HRSA in defending the agency’s 340B patient definition against drugmaker AbbVie’s lawsuit.
